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Abstract: Coronavirus disease (COVID-19) was firstly reported at the end of 2019. The disease rapidly spread all around the world in a
few months and was declared a worldwide pandemic by WHO in March 2020. By April 9, there were 1,436,198 confirmed COVID-19
cases in the world, nearly with 6% mortality rate. This novel infectious disease causes respiratory tract illness that may generally occur as
mild upper respiratory tract disease or pneumonia. In older patients and/or patients with underlying conditions, it may result in acute
respiratory distress syndrome, multi organ failure and even death. According to the current literature, children account approximately for
1%–5% of diagnosed COVID-19 cases. Generally, COVID-19 seems to be a less severe disease for children than adults. Approximately
90% of pediatric patients are diagnosed as asymptomatic, mild, or moderate disease. However, up to 6.7% of cases may be severe. Severe
illness is generally seen in patients smaller than 1 year of age and patients who have underlying disesases. The epidemiological and
clinical patterns of COVID-19 and treatment approaches in pediatric patients still remain unclear although many pediatric reports
are published. This review aims to summarize the current epidemics, clinical presentations, diagnosis, and treatment of COVID-19 in
pediatric patients.
Keywords: Novel corona virus, COVID-19, pediatrics

1. Introduction
Many cases of pneumonia with an unknown origin were
observed in Wuhan, Hubei Province, China [1,2]. It was
reported that most of these patients exposed to the Huanan
Seafood Wholesale Market. The disease spread rapidly, to
other parts of China, and then globally, to many countries
across six continents.
On January 3, 2020, the Chinese Center for Disease
Control and Prevention (China CDC) confirmed a novel
member of enveloped RNA coronavirus as the cause of
this disease1. The World Health Organization (WHO)
described it as the 2019 novel coronavirus (2019-nCoV) on
January 7, 2020. After a short period, WHO has declared
the COVID-19 a public health emergency of international
concern on January 302. Since then, the disease affected

more than 177 countries globally. On February 11, 2020,
this illness was named as the 2019 coronavirus disease
(COVID-19) by WHO [3].
The first cases detected in Europe were reported from
France on January 24, 2020, many European countries
reported cases following France. In a short time, many
people from many different countries in Europe were
affected [4]. The first case from Turkey was reported
on March 13, 2020. By April 9, there were 1,436,198
confirmed COVID-19 cases in the world, and total deaths
were 85,5223.
The first confirmed pediatric case of Severe Acute
Respiratory Syndrome (SARS)-CoV-2 infection was
reported in Shenzhen on January 20 [5], and by January
31, more than 20 pediatric cases were reported in China
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[6]. Thereafter, many pediatric case reports and case
series were reported. But the epidemiological and clinical
patterns of the COVID-19 in pediatric patients still remain
largely unclear despite the worldwide spread [2]. This
report aims to identify the epidemiological characteristics,
clinical findings, and treatment suggestions in pediatric
patients with the 2019 novel coronavirus disease.
2. Virology and pathogenesis
Coronaviruses (CoVs) are a group of related zoonotic
viruses that cause disease in mammals and birds. They are
enveloped positive-stranded RNA viruses with a crownlike appearance under an electron microscope, because of
the spike glycoproteins on the envelope [7].
Coronaviridea family constitute the subfamily
Orthocoronavirinae. Orthocoronavirinae subfamily
classifies into four genera of CoVs: Alphacoronavirus
(alphaCoV),
Betacoronavirus
(betaCoV),
Deltacoronavirus (deltaCoV), and Gammacoronavirus
(gammaCoV). Alpha-corona viruses include species of
Human coronavirus 229E, Human coronavirus NL63,
which concern human illnesses. Beta-corona viruses
genus divides into four lineages (subgroup A, B, C and
D) [8]. Subgroup A includes Betacoronavirus 1 (Human
coronavirus OC43) and Human coronavirus HKU1 as
human pathogens. Subgroup B includes Severe acute
respiratory syndrome-related coronavirus (SARS-CoV,
SARS-CoV-2). Subgroup C includes the Middle East
respiratory syndrome-related coronavirus as a human
pathogen [8].
Common human coronaviruses are; HCoV-OC43,
HCoV-HKU1 HCoV-229E, and HCoV-NL63. They
generally cause common cold and mild upper respiratory
infections in immunocompetent individuals. Lower
respiratory infections may occur in older or immunecompromised people [8].
Other important human CoVs are; SARS-CoV,
SARS-CoV-2, and Middle East Respiratory Syndrome
(MERS)-CoV. They cause epidemics with variable clinical
severity presenting with respiratory and extra-respiratory
manifestations. Concerning SARS-CoV, MERS-CoV,
the mortality rates are up to 10% and 35%, respectively.
As SARS-CoV-2 belongs to the beta-CoVs category, it
has round or elliptic and often pleomorphic form, and a
diameter of approximately 60–140 nm [8].
When it was evaluated genetically, the consistency of
whole genome-wide nucleotide sequences of 2019-nCoV
was consistent with SARS-like coronavirus in bats (bat-SLCoVZC45) and the accordance ranged from 86.9% [9] to
89% [5], and 82% with that of human SARS-CoV [10].
According to this finding, the new virus was called
SARS-CoV-2. The single-stranded RNA genome of the
virus contains 29891 nucleotides, encoding for 9860

amino acids. These genomic analyses suggest that SARSCoV-2 probably evolved from a strain found in bats, but
its origins are not entirely understood [8].
SARS-CoV-2 is known to be sensitive to ultraviolet
rays and heat. Like other coronaviruses, these viruses can
be inactivated by lipid solvents, including either (75%),
ethanol, chlorine-containing disinfectant, peroxyacetic
acid and chloroform except for chlorhexidine [6,8].
The structure of the receptor-binding gene region is
very similar to that of the SARS coronavirus, and the virus
has been shown to use the same receptor, the angiotensinconverting enzyme 2 (ACE2), for cell entry [9,11]. When
the virus enters the cell, the viral genome begins to replicate
and translates structural proteins. After the process inside
the cytoplasm, the vesicles containing the virus particles
fuse with the plasma membrane to release the virus.
After the entry of virus to the cell, antigen presentation
cells (APC) -the main part of antiviral immunity- begin
to present the antigens. Afterward, antigen presentation
subsequently stimulates virus-specific B and T cells
and they mediate the body’s humoral immunity and
immunoglobulin M and G production begins. Specific
IgM antibodies disappear approximately at the end of
12th week. IgG antibody lasts for a longer time and the
SARS-specific IgG antibodies primarily are S-specific and
N-specific antibodies [12]. There are more researches
on the cellular immunity of coronavirus compared to
humoral immunity [8]. The current data seems to indicate
that the viral infection is capable of producing an excessive
immune reaction in the host. In some cases, a ‘cytokine
storm’ occurs of which the effect is extensive tissue damage.
Interleukin 6 (IL-6) triggers this storm, which is produced
by activated leukocytes and acts on a large number of cells
and tissues. This cytokine storm may result in an acute
systemic inflammatory syndrome characterized by fever
and multiple organ dysfunction [8].
A report in Lancet showed that acute respiratory
distress syndrome (ARDS) is the main cause of death
in COVID-19 patients. ARDS is known as the common
immunopathological result for SARS-CoV-2, SARS-CoV
and MERS-CoV infections. The cytokine storm results
with a violent attack by the immune system to the body,
which cause ARDS and multiple organ failure, and finally
lead to death in severe cases of SARS-CoV-2 infection,
just like in SARS-CoV and MERS-CoV infection [13].
The cytokine storm and the deadly uncontrolled systemic
inflammatory response resulting from the release of large
amounts of proinflammatory cytokines (IFN-a, IFN-g,
IL-1b, IL-6, IL-12, IL-18, IL-33, TNF-a, TGFb, etc.) and
chemokines (CCL2, CCL3, CCL5, CXCL8, CXCL9,
CXCL10, etc.) by immune effector cells ends with ARDS
in SARS-CoV infection [14]. Similar to those with SARSCoV, individuals with severe MERS-CoV infection show
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elevated levels of IL-6, IFN-a, and CCL5, CXCL8, CXCL10 in serum compared to those with the mild-moderate
disease [11].
It is noted that, COVID-19 children are less susceptible
to COVID-19 and that seem to be affected less commonly
than adults [3,15]. Suggested reasons include having a
more active innate immune response, healthier respiratory
tracts (because of not exposing to cigarette smoke and air
pollution as adults), and fewer underlying disorders. In
addition, they are generally overprotected by parents, and
if there is not any positive case in family, the possibility
of being infected decreases [15]. A dangerous and
uncontrolled immune response in adults may also explain
with a robust immune response which may lead to ARDS
[15]. It was found that ACE2 expression in rat lung has been
found to dramatically decrease with age [15]. This finding
may not be consistent with a relatively low susceptibility
of children to COVID-19. On the other hand, studies
show that ACE2 is involved in protective mechanisms of
the lung. It may protect against severe lung injury induced
by respiratory virus infection in an experimental mouse
model and in pediatric patients [16,17]. The difference
between adults and children in case of severity may be
related to differences in receptors in the Renin-angiotensin
system (RAS) and altered inflammatory responses to
pathogens [18].
3. Transmission
The first cases of the COVID-19 had the history of direct
exposure to the Huanan Seafood Wholesale Market
of Wuhan. So the animal-to-human transmission was
presumed as the main mechanism at the beginning. In
a short period, subsequent cases without any history of
visiting the market were reported. Hence, it was stated
that the virus could also be transmitted from human-tohuman. The most frequent source of COVID-19 spread
are symptomatic patients [8]. It is certain that the main
sources of the infection are patients infected by 2019-nCoV
with or without clinical symptoms [5,6], but in addition,
patients in the incubation period may also have potency
to transmit the virus. It is suggested that individuals who
remain asymptomatic during disease could transmit the
virus too [8].
According to the current data, the novel virus is
primarily transmitted through respiratory droplets and
contact routes4. Respiratory droplets transmit the virus
when patients cough, talk loudly or sneeze and transmission
is possible via close contact (e.g., contact with the mouth,
nose or eye conjunctiva by a contaminated hand) [6].

According to the data reported by the China Center for
Disease Control (CDC) and local CDCs, the incubation
time is generally 3 to 7 days and up to 2 weeks as the
longest time from infection to symptoms was 12.5 days
(95% CI, 9.2–18) [2]. On average, each patient transmits
the infection to an additional 2.2 individuals. Remarkably,
estimations of the R0 of the SARS-CoV epidemic in 2002–
2003 were approximately 3 [19].
No airborne transmission was reported in an analysis
of 75,465 COVID-19 cases in China [20]. Airborne
transmission may be possible in only specific situations
and settings in which procedures or support treatments
that generate aerosols are performed, this transmission
route especially concerns health care personnel.4
There is some evidence that COVID-19 infection may
result with intestinal infection and virus can be present in
faeces. However, there have been no reports of faecal-oral
transmission of the COVID-19 virus to date.4 In a study
of Xing et al., clearance of SARS-CoV-2 in respiratory
tract occurred within two weeks after the decrease in
fever, whereas viral RNA remained detectable in stools of
pediatric patients for longer than 4 weeks [21].
Mother to infant transmission of SARS-CoV-2
is controversial (through breast-milk or vertical
transmission). In pregnancy, viremia rates seem to be low,
shown as 1% in Wang’s report [22]. This finding suggests
that placental seeding and vertical transmission is unlikely.
In Schwartz’s review, 38 pregnant women with COVID-19
were reported, and, no cases of intrauterine transmission
were documented [23]. On the other hand, many possible
cases have been reported that presenting newborns
delivered from COVID-19 pregnants, with increased Ig m
levels but negative polymerase chain reaction tests results
after cesarean delivery or reports presenting neonatal
pneumonia due to COVID-19, with nasopharyngeal and
anal cultures and polymerase chain reaction tests were
positive for SARS-CoV-2.
But positive IgM results alone are not definitive
evidence of in utero infection. So early infant infection
may have been due to postnatal contact with infected
parents or caregivers [24]. Thus, there is a suspect, but no
certain evidence of vertical transmission for COVID-19
yet and further reports and studies are warranted.
Transmission with breast milk is another matter of
debate. It is not clear if the virus transmits through breast
milk or via feeding the baby. According to Wang’s report, it
is suggested that infants should not be fed with breast milk
from mothers with neither confirmed nor suspected of
2019-nCoV. If breast milk of these mothers tested negative
for 2019-nCoV, then infants may be fed with breast milk.
Using donor milk can be considered after being screened

World Health Organization (2020). Modes of transmission of virus causing COVID-19: implications for IPC precaution
recommendations. Scientific brief. 29 March 2020 [online]. Website https://www.who.int/news-room/commentaries/detail/modes-oftransmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations [accessed 10 April 2020].
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for 2019-nCoV, in case of excretion of the virus into the
milk during the incubation period [25]. On contrary,
another study presented that no virus was found in the
maternal milk of six COVID-19 patients [26]. Another
recent study by Davanzo et al, according to the latest data,
it was advised that if a mother diagnosed or suspected
as COVID‐19 or under investigation for COVID‐19
whether asymptomatic or paucisymptomatic at delivery,
breastfeeding is advisable, under strict measures of
infection control [27].
In concordance with this study when a mother with
COVID‐19 is too sick to care for the newborn, the neonate
will be managed separately and fed fresh expressed breast
milk, with no need to pasteurize it, as human milk is not
believed to be a vehicle of COVID‐19 [27]. WHO suggests
that women with COVID-19 can breastfeed if they wish
to do so. However, it is mentioned that there is still a risk
for droplet transmission via close contact during feeding
(breastfeeding or bottle feeding). So, it is important to
carry out precautions to prevent transmission. Mothers
should practice respiratory hygiene during feeding,
wearing a mask where available, wash hands before and
after touching the baby, and routinely clean and disinfect
what they have touched5.
4. Epidemiology
Pediatric cases reported during the previous outbreaks of
SARS in Hong Kong and MERS in South Korean, were very
few [28]. In addition, mortality rate of SARS and MERS in
the adults was very high, but there were no fatalities in the
pediatric cases [28]. These findings indicated that children
appeared to have a milder form of the disease caused by
the coronaviruses [2]. Current data about COVID-19, in
pediatrics is similar to SARS and MERS in case of disease
severity and mortality and shows that children of all ages
can get COVID-19, but they seem to be affected less
commonly than adults [3]6.
The first confirmed pediatric case of SARS-CoV-2
infection was reported in Shenzhen on January 20 [5],
and by February 10, a total of 398 confirmed pediatric
cases were reported from China, excluding the Hubei
Province [2]. It is well known that pediatric cases are
generally identified at that time in a familial cluster or
and generally are infected by one sick parent or family
member. According to a study, 71.2% (183/257) of infected
children were reported having a household contact [29].
In another study by Lu, 90.1% of patients were reported to

be with family clusters [30]. But at the explosion stage of
the outbreak, children may become a significant spreader
[31].
The surveillance definitions and criteria are changing
during the pandemic, but still data from many different
countries, are similar with these studies and the proportion
of pediatric cases is within this range.
Less than 1% of the cases were in children younger
than 10 years of age in the review of 72,314 cases reported
by the Chinese Center for Disease Control and Prevention
[32]. According to a study that analyzed 44,672 COVID-19
cases from China by mid-February 2020, 0.9% of patients
were less than 10 years of age and 1.2% were between 10
and 20 years of age [33]. According to Statista Research
Department, Italy, 1.6% of total patients were from 0 to18
age7. In a systematic literature review (between January
1and March 18, 2020), children were 1 to 5 percent of
diagnosed COVID-19 cases [34]. To date, there are about
149,760 laboratory-confirmed cases reported from United
States, and only 1.7 percent are in children.6
In a report of 171 pediatric cases, reported by Lu et al.,
median age of patients was 6,7 year (1 day–15 years) and
60.8% were male.
In this case series, 18.1% of patients were <1 year
of age, 23.4% were 1–5 years, 33.9% were 6–10 years,
24.6% were 11–15 years [30]. In Dong’s study, there were
728 confirmed cases and 1407 suspected cases. 17.6% of
pediatric cases were <1 year of age, %23 were 1–5 years,
24.5% were 6–10 years, %19.3 were 11–15 years, %15.6
were >15 years. The median age of all patients was 7 years
and 56.6% of patients were male [3]. According to US
data, among all 2,572 COVID-19 cases in children, the
median age was 11 years (0–17 years). Approximately onethird of reported pediatric cases 32% were between 15–17
years of age, 27% were between 10-14 years of age. Fifteen
percent of cases were aged <1 year, 11% of cases were aged
1–4 years, and 15% of cases were aged 5–9 years. Males
comprised 57% of cases in the population in which sex
information was obtained; among 184 cases in children
whose information of exposure were available, 9 % had a
history of travel, and 91% had a history of contact with a
COVID-19 patient in the household or community.6
By 30.03.2020, there were 11535 total cases, of which
117 (1%) were pediatric in Turkey. The mean age was 8
years (1day–17 years). The 13.6% of cases were <1 year.
There were 3 neonatal cases. Nearly 53% of cases were male.
Patients with a history of contact were 48.7%. Only 1.7%

World Health Organization (2020). Q&A on COVID-19, pregnancy, childbirth and breastfeeding [online]. Website https://www.who.
int/news-room/q-a-detail/q-a-on-covid-19-pregnancy-childbirth-and-breastfeeding [accessed 10 April 2020].
5
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of cases had a history of travel abroad. Turkish citizens
comprised 93.1% of cases, but 6.9% were immigrants8.
5. Clinical findings
According to the available data, COVID-19 in children
appears to be usually mild. A minority of children with
COVID-19 require hospitalization. By March 6, among
2572 laboratory-confirmed cases of COVID-19 in children
reported from the US, the estimated rate of hospitalization
differed from 6% to 20%, and 0.58%–2.0% of them were
admitted to an ICU.6 In this report, children aged <1 year
had the highest percentage (15%–62%) of hospitalization
among pediatric patients with COVID-19. Among 95
children aged <1 year with known hospitalization status, 59
(62%) were hospitalized, including five who were admitted
to an ICU. The percentage of patients hospitalized among
those aged 1–17 years was lower (estimated range = 4.1%–
14%), with little variation among age groups.6
Fever and cough are the most common reported
symptoms in children [30]. Fever (subjective or
documented), cough, and shortness of breath were more
common among adult patients aged 18–64 years (93%
reported at least one of these).
In contrast, these signs and symptoms were less
frequently reported among pediatric patients (73%). In the
case series from the United States, complete information
about symptoms was available for 291 children; 56 percent
had a fever, 54 percent had a cough, and 13 percent has
shortness of breath; at least one symptom was observed
in 73% of children6 On the other hand, these ratios were
71%, 80%, and 43%, respectively, in adults. Sore throat,
myalgia, headache, and diarrhea were also reported rarely
by pediatric patients.6
In another series of 1391 children evaluated for
COVID-19 at Wuhan Children’s Hospital, 171 (12%)
had confirmed SARS-CoV-2 infection (by identification
of RNA). In this report, 15.8% percent of children with
confirmed infection were asymptomatic, 19.3% had
upper respiratory infection, and 64.9% had pneumonia.
Fever was the most common symptom, occurring at
some point in illness in approximately 41.5%. Other
common symptoms included cough (48.5 percent) and
pharyngeal erythema (46.2%). Less common symptoms
included fatigue, rhinorrhea/nasal congestion, diarrhea,
and vomiting. (changing between 5% and 9%). A total
of 12 asymptomatic patients had radiologic features of
pneumonia. A total of 21 patients were in stable condition
in the general wards, and 149 were discharged from the
hospital [30].
According to Dong et al.’s report, regarding the
severity, 94 (4.4%), 1088 (51.0%), and 826 (38.7%) cases
were diagnosed as asymptomatic, mild, or moderate,
8

respectively; and accounted for 94.1% of all cases. Severe
and critical cases were 6.7% and 0.7% of patients [3]. The
clinical features, laboratory testing, and chest radiograph
imaging state the severity of COVID-19 [35]. Similar
clinical manifestations have been reported in smaller case
series from China [36–38].
According to the surveillance data from Turkey, 50.4%
of pediatric cases had a mild disease, and 0.8% had severe
disease. Intensive care hospitalization rate was 4.27% and
80% of them were under one year of age.8
Another critical age group in pediatrics is the neonatal
period. Neonates are generally associated with milder
disease [26,39]. In a report about COVID-19 in the
neonatal period, it was found that the clinical symptoms
of 33 neonates with or at risk of COVID-19 were obscure,
and favorable outcomes were seen.
Of 33 neonates born to COVID 19 mothers, 30 had
negative test results, but there were 3 neonates with
symptomatic COVID-19. The most seriously ill neonate
was possibly symptomatic because of prematurity,
asphyxia, and sepsis, rather than SARS-CoV-2 infection
[40]. In a case series of neonates, born to COVID-19
mothers, the 2019-nCoV nucleic amplification test results
were negative for all neonates; thus there was no evidence
of vertical transmission of 2019- nCoV via the placenta
and they were all fine, so no antiviral treatment was
administered to the neonates [41].
Although most children appear to havemild or
moderate disease and recover within one to two weeks
of disease onset, severe cases may also be seen, especially
who are with underlying conditions. Children with certain
serious underlying conditions and who are <1 year of
age are at higher risk for severe disease [3].6 Among
345 children from the United States with laboratoryconfirmed COVID-19 and complete information about
underlying conditions, 23% had an underlying condition.
Common underlying conditions were chronic pulmonary
disease (including asthma), cardiovascular disease, and
immunosuppression (e.g., related to cancer, chemotherapy,
radiation therapy, hematopoietic cell or solid organ
transplant, high doses of glucocorticoids). Blood disorders,
chronic kidney disease undergoing dialysis, chronic liver
disease, pregnancy, endocrine disorders (e.g., diabetes
mellitus), neurologic and neurodevelopmental conditions
(e.g., cerebral palsy, epilepsy, intellectual disability, spinal
cord injury) are significant reasons for severe disease.
Among the 295 pediatric cases for which information
on both hospitalization status and underlying medical
conditions was available, 28 of 37 (77%) hospitalized
patients, (including patients admitted to an ICU), had
one or more underlying medical condition; among 258
patients who were not hospitalized, 30 (12%) patients had

Turkish Republic Ministry of Health (2020), COVID19 Surveillance data (unpublished).
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underlying conditions. Three deaths were reported among
the pediatric cases included in this analysis; however, the
reason for death as COVID-19 is not confirmed yet.6 In
the study by Lu et al., during hospitalization, 3 patients
required intensive care support and invasive mechanical
ventilation; all had coexisting conditions [hydronephrosis,
leukemia (for which the patient was receiving maintenance
chemotherapy), and intussusception] [30]. Epidemiologic
and clinical features of pediatric case series are summarized
in Table.
6. Diagnosis
6.1. Diagnostic criteria
A diagnostic approach for COVID begins with the
compatibility of exposure history, symptoms, and findings
to the case definition criteria. Case definitions are based
on the currently available data. Diagnostic criteria are
regularly revised as new information accumulates.
Definitions should be revised according to their local
epidemiological data and individual factors. All countries
are encouraged to publish definitions used online and
in regular situation reports and to document periodic
updates to definitions, which may affect the interpretation
of surveillance data9.
Pediatric patients should be evaluated according to
complaints, clinical findings, and a history of exposure
[35]. Firstly it should be stated if a child was in contact
with a COVID-19 patientin the last two weeks period
or has been to an endemic area for COVID-19. This
information contributes to determine the level of risk,
as low, medium, or high. Afterward, suspected cases are
explored for the following: A- the presence of fever, any
respiratory symptom, gastrointestinal symptoms like
diarrhea. B- complete blood count should be tested to find
out leukopenia, lymphopenia, and C-reactive protein is
also tested in case of an increase. C- chest screening should
be done to find out any infiltration if present. Further
examination is carried out for suspected patients. If a case
is positive for nCoV-2019 in nasal/pharyngeal swap or
blood samples by polymerase chain reaction (PCR) assay
OR if samples from the respiratory tract or blood samples
are similar to nCoV-2019 is similar genetically, then the
case is defined as confirmed [3].
Another critical issue in diagnosis is the method of
optimal sampling choice for diagnosing COVID-19 [35].
In a study of 205 patients with COVID-19 who were
sampled at various sites, the highest rates of positive viral

RNA tests were reported from bronchoalveolar lavage (95
percent, 14 of 15 specimens) and sputum (72 percent, 72
of 104 samples). Still, oropharyngeal swap test results were
as low as 32% [22]10.
6.2. Laboratory examinations
White blood cell count is normal in general. But leucopenia
may be seen, with decreased lymphocyte count. C-reactive
protein (CRP) may be normal or increased. Interleukin-6
(IL-6) is also generally high in patients, especially in severe
cases.
Procalcitonin (PCT) is normal in most cases, and
PCT > 0.5 ng/mL might be a sign of secondary bacterial
infection. Elevation of liver enzymes, muscle enzymes,
and myoglobin, and increased level of D-dimer might be
seen in severe cases [6].
6.3. Imaging features
In the early stage of pneumonia cases, chest images show
multiple small patchy shadows and interstitial changes,
remarkable in the lung periphery. Severe cases can
further develop to bilateral multiple ground-glass opacity,
infiltrating shadows, and pulmonary consolidation, with
infrequent pleural effusion [30].
A Chest CT scan shows pathologic findings more
clearly, including ground-glass opacity and segmental
consolidation in bilateral lungs, especially in the lung
periphery. In children with severe infection, multiple lobar
lesions may be present in both lungs. In the Lu et al.’s study
of pediatric cases, the most common radiologic finding
was bilateral ground-glass opacity (32.7%). Other findings
were local patchy shadowing 18.7%, bilateral patchy
shadowing 12.3%, and interstitial abnormalities 1.2% [30].
Pleural effusion was not seen.
In a pediatric case series, among 15 confirmed pediatric
COVID-19 cases, 6 patients had no lesions, while 9
patients had pulmonary inflammation lesions on their first
chest CT images. Small nodular ground-glass opacities
were found in 7 cases, and speckled ground-glass opacities
were found in 2. Among the patients whose second PCR
test was negative, chest CT images showed fewer lesions
in 2 cases, no lesion in 3 cases, and no improvement in
1 case. The other 9 cases were still positive in the second
nucleic acid test. Six of them showed similar chest CT
inflammation, while 3 patients had new lesions, which
were all small nodular ground-glass opacities [42].
7. Treatment
There are many published and ongoing studies about the

World Health Organization (2020). Global surveillance for COVID-19 caused by human infection with COVID-19 virus. Interim
guidance 20 March 2020 [online]. Website https://www.who.int/docs/default-source/coronaviruse/global-surveillance-for-COVID-v19-final200321-rev.pdf [accessed 12 April 2020].
9

World Health Organization (2020). Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-2019). February
16-24, 2020 [online]. Website http://www.who.int/docs/default-source/coronaviruse/who-china-jointmission-on-covid-19-finalreport.pdf [accessed 04. March 2020].
10

597

TEZER and BEDİR DEMİRDAĞ / Turk J Med Sci
Table. Epidemiologic and clinical characteristics of pediatric patients.
Dong et al.

Lu et al.

CDC/MMWR
USA

Turkey*

Total confirmed patients

728 (confirmed)
1407 (suspected)

171

2572

117

Sex, male (%)

56.6

60.8

57

52.9

Median age (yr)

7 (IQR: 2–13)

6.7 (1d–15 yr)

11 (0–17)

8 (1d–17yr)

Age distribution (%)

<1 year
1-5 year
6-10 year
11-15 year
>15 years

17.6
23
24.5
19.3
15.6

18.1
23.4
33.9
24.6
Not included

15
11 (1-4 yr)
15 (5-9 yr)
27 (10-14 yr)
32

13.6
20.5
16.2
28.2
21.3

Clinical presentation

Asymptomatic
Mild disease
Moderate disease
Severe illness

4.4
51.0
38.7
7.4

15.8
19.3
-

-

50.4
0.8

1

1

3

0

Mortality (n)

treatment of COVID-19, but these studies are generally on
adult patients. In the pediatric era, treatment strategies are
commonly modified from adult reports, and future studies
are warranted.
Home care facilities seem to be feasible for patients
with asymptomatic infection, mild infection (e.g., fever,
cough, and/or myalgias without dyspnea, hypoxia, and
tachypnea), and having no underlying condition.These
patients should adequately be isolated in the outpatient
setting11,12.
Treatment modalities may be summarized in the
following subtitles.
7.1. Symptomatic and supportive care
Symptomatic and supportive care is similar to other
upper respiratory or gastrointestinal clinical syndromes
like common cold or acute gastroenteritis. The general
strategies include resting and supportive treatments,
sufficient calorie, and water intake, maintaining waterelectrolyte balance, and homeostasis [6]. Patients
and household members should be educated about
personal hygiene, infection control measures to prevent
the infection from spreading to household contacts.
Outpatients with COVID-19 should stay at home and try
to separate themselves from other people and animals in

the household. There is an extensive guideline prepared by
WHO for home care patients.12 The optimal duration of
home isolation is detailed in another section.
7.2. Antibiotics
Antimicrobial stewardship is crucial. There is no need for
antibiotic treatment routinely. Irrational use of antibiotics
(especially broad-spectrum) should be avoided. Patients
should be monitored carefully in case of bacterial
coinfection. If there is clinical or laboratory evidence of
secondary bacterial infection, appropriate antibiotics
should be used appropriately [6].
7.3. Management for oxygen therapy and mechanical
ventilatory support
Patients with respiratory distress and severe acute
respiratory illness (SARI), including hypoxemia or
shock, should be given supplemental oxygen therapy
immediately, providing the level of >94%. Children with
severe respiratory distress, central cyanosis, shock, coma,
or convulsions should receive airway management and
oxygen therapy. Nasal cannula is preferred in young
children13. High-flow oxygen and noninvasive positive
pressure ventilation have been used. But these procedures
might cause aerosolization, and specific isolation

Centers for Disease Control and Prevention (2020). Interim clinical guidance for management of patients with confirmed coronavirus
disease (COVID-19). Revisions were made on April 3, 2020 [online]. Website https://www.cdc.gov/coronavirus/2019-ncov/hcp/
clinical-guidance-management-patients.html [accessed 10 April 2020].
11

World Health Organization (2020).Home care for patients with COVID-19 presenting with mild symptoms and management of their
contacts [online]. Website https://www.who.int/publications-detail/home-care-for-patients-with-suspected-novel-coronavirus-(ncov)infection-presenting-with-mild-symptoms-and-management-of-contacts [accessed 10 April 2020].
12

World Health Organization (2020).Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is
suspected. Interim guidance 13 March 2020 [online]. Website https://www.who.int/publications-detail/clinical-management-of-severeacute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected [accessed 10 April 2020].
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precautions may be needed [43].
When respiratory distress keeps rising despite standard
oxygen therapy, advanced oxygen/ventilatory support
should be provided. If improvement is not possible,
mechanical ventilation with endotracheal intubation and a
protective lung ventilation strategy should be adopted [6].
7.4. Antiviral therapy
There is not an approved COVID-19 specific therapy for
pediatric patients. Different agents were tried in some
cases, but there is not sufficient data to make general
recommendations for routine use. According to a recent
report by Sanders, no proven effective therapies for this
virus currently exist, and the most promising treatment
was remdesivir [44]. Some of these agents will be discussed
as follows.
7.4.1. Hydroxychloroquine/chloroquine
There is not enough evidence showing whether
hydroxychloroquine or chloroquine has a role in the
treatment of COVID-19. There are in vitro studies that
show both chloroquine and hydroxychloroquine inhibit
SARS-CoV-2 in vitro, although hydroxychloroquine
appears to be more potent [45]. Treatment guidelines from
China’s National Health Commission supported the use of
chloroquine. It was shown that the progression of disease
was reduced, and the duration of symptoms decreased
[46]. However, primary data supporting these claims have
not been published yet. A randomized trial of patients with
mild COVID-19 pneumonia without hypoxia reported
that adding hydroxychloroquine to the standard of care
resulted in clinical and laboratory improvement, but there
are concerns about the methodology of this study14.
The Infectious Disease Society of America (IDSA)
guideline panel for COVID-19 treatment, recommends
hydroxychloroquine/chloroquine in the context of a
clinical trial. But there is a knowledge gap15.
There is not a specific dosage recommendation for
hydroxychloroquine in pediatric patients. Some experts
from Iran suggested to use, 3–5 mg/kg/day (max dose 400
mg) hydroxychloroquine sulfate iv, in pediatric patients,
twice daily for five days with careful monitoring for
cardiac arrhythmias including QT interval prolongation
or torsades de pointes [47]. This drug may be used in
pregnancy and lactation if the benefit outweighs risks [44].
Concurrent
use
of
azithromycin
with
hydroxychloroquine for treating COVID-19 is not
routinely recommended. One study suggested the use of
azithromycin in combination with hydroxychloroquine
was associated with more rapid resolution of virus
detection than hydroxychloroquine alone [48]. Still,

another small observational study in patients with more
severe illness did not suggest rapid viral RNA clearance
with the combination [49]. Both azithromycin and
hydroxychloroquine are associated with QTc prolongation,
and combined use may potentiate this adverse effect.
The IDSA guideline panel recommends the use of the
hydroxychloroquine and azithromycin combination only
be used in the context of a clinical trial.15
7.4.2. Interferon-α2b
According to Chen’s review in pediatric patients,
interferon-α2b nebulization (100,000–200,000 IU/kg for
mild cases, and 200,000–400,000 IU/kg for severe cases,
two times/day for 5–7 days.) can be applied [6].
7.4.3. Lopinavir-ritonavir
Lopinavir ritonavir combination appears to have little
to no role in the treatment of SARS-CoV-2 infection.
This drug is a protease inhibitor and primarily used
for HIV infection. According to a study, it has in vitro
activity against the SARS-CoV [50] and appears to have
some activity against MERS-CoV in animal studies [51].
Nevertheless, there was no significant improvement in
clinical outcomes or mortality in a randomized trial of 199
patients between the lopinavir-ritonavir group and those
who received standard of care alone [52].
Among patients who have been admitted to the hospital
with COVID-19, the IDSA guideline panel recommends
the combination of lopinavir/ritonavir only in the context
of a clinical trial. There is also a knowledge gap in this
condition.15
7.4.4. Remdesivir
Remdecivir is a novel nucleotide analog that has activity
against SARS-CoV-2 in vitro and related coronaviruses
(including SARS and MERS-CoV) both in vitro and in
animal studies [53]. It is also potent in vitro activity against
SARS-CoV-2, but it is not approved yet and currently, is
being tested in ongoing randomized trials [44].
A recent case series of 53 patients with severe
COVID-19 pneumonia who received remdesivir
under a compassionate-use protocol reported clinical
improvement in 68% after a median follow-up of 18 days,
with 13% mortality and a generally acceptable toxicity
profile [54]. However, there was no comparison group
of similar patients who received standard care at the
participating institutions.
Efficacy in pediatric patients and optimal dosing are
not established yet. A dosing regimen of 5 mg/kg/dose iv
once daily (max: 200 mg) on day 1, followed by 2.5 mg/kg/
dose iv once daily (max: 100 mg) was used in 41 pediatric
patients (including 2 neonates) who received remdesivir in

Chen Z, Hu J, Zhang Z et al. Efficacy of hydroxychloroquine in patients with COVID-19: Results of a randomized trial. MedRxiv
(2020). doi:10.1101/2020.03.22.20040758v2
14

Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L et al. Infectious Diseases Society of America Guidelines on the Treatment
and Management of Patients with COVID-19 - 2020 [online]. Website www.idsociety.org/COVID19guidelines [accessed 11 April 2020].
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a phase 3 Ebola study16.The optimal duration of therapy for
COVID-19 is unknown.
7.4.5. Favipiravir
Favipiravir was approved for the treatment of novel
influenza in China. Clinical trials of favipiravir for
treatment of COVID-19 are going on, but there is not
any evidence for pediatric patients yet. It is an RNA
polymerase inhibitor. It is thought to have potential
antiviral action on SARS-CoV-2. In February, a clinical
trial on favipiravir for the treatment of COVID-19 was
initiated, and results were promising. The preliminary
results from a total of 80 patientsindicated that favipiravir
had more potent antiviral action than lopinavir/ritonavir17.
There is no specific dosing recommendation for favipiravir
in pediatric COVID-19 patients, but doses that were used
in the treatment of the Ebola virus or influenza virus may
be appropriate.
7.5. Glucocorticoids
WHO and CDC claim that systemic glucocorticoids should
not be used in patients with COVID-19, unless there are
other indications (e.g., exacerbation of chronic obstructive
pulmonary disease). A pediatric review reports that they
can be used in severe cases when indicated, but its efficacy
needs further evaluation [6]. Many studies on SARS and
MERS-CoV showed a lack of effectiveness and possible
harm [55]. The IDSA guideline panel also suggests against
the use of corticosteroids (conditional recommendation,
very low certainty of the evidence). The same guideline
recommends the use of corticosteroids for patients only
with ARDS due to COVID-19 in the context of a clinical
trial.15
7.6. Tocilizumab
Tocilizumab is an IL-6 receptor inhibitor used for
rheumatic diseases and cytokine release syndrome. It was
reported that severe COVID-19 patients had elevated
IL-6 levels, and there are case reports which describe
good outcomes with tocilizumab [56]. Tocilizumab may
be recommended for severe COVID-19 patients and
patients with high IL6 levels18. The IDSA guideline panel
recommends tocilizumab only in the context of a clinical
trial. Xu et al. reported that treatment with tocilizumab

reduced mortality19. However, this conclusion remains
highly uncertain, given the lack of a contemporaneous
control or adjustments for confounding factors.
7.7. Organ function support
WHO recommends recognizing septic shock in children
with any hypotension or two or more of the following:
altered mental state; tachycardia or bradycardia; prolonged
capillary refill (> 2 s) or feeble pulses; tachypnea; mottled
or cold skin or petechial or purpuric rash; increased
lactate; oliguria; hyperthermia or hypothermia.13
Antimicrobial therapy should be started, and fluid bolus
should be initiated. In case of circulation dysfunction,
vasoactive drugs may be used to improve microcirculation
[6]. In children, epinephrine is considered first-line,
while norepinephrine can be added if shock persists
despite the optimal dose of epinephrine. Continuous
blood purification should be considered in cases of
multiple organ failure (especially acute kidney injury),
or capacity overload and life-threatening imbalance of
water, electrolyte, and acid-base. If combined with liver
failure, plasma exchange is feasible.13 Extracorporeal
membrane oxygenation (ECMO) has been proven to be
an effective therapy in the treatment of respiratory failure
ARDS, so it may also be effective in the treatment of severe
COVID-19. Since there is a lack of clinical trial of ECMO
on COVID-19, we could not conclude whether SARSCoV-2-infected patients have benefited from ECMO at
this time [57].
7.8. Intravenous immunoglobulin and Immun
Convalescent Plasma [58]
In this current pandemic, there are reports that
convalescent plasma has been used in China to treat
patients with COVID-19 [59].
In a pilot study of 10 patients with severe COVID-19,
the investigators collected convalescent plasma with
neutralizing antibody titers at or exceeding a 1:640
dilution20. Transfusion of convalescent plasma resulted in
no serious adverse effect in the recipients. Improvement
was shown in symptoms within 1–3 days of transfusion;
they also demonstrated radiological improvement in
pulmonary lesions. Although there are methodologic

National Institute of Allergy and Infectious Diseases (NIAID) (2020). Investigational Therapeutics for the Treatment of People With
Ebola Virus Disease. [online]. Website https://clinicaltrials.gov/ct2/show/NCT03719586? term=randomized+ebola&draw=2 [accessed
30 March 2020].
16

News (in Chinese) [online]. Website http://www.szdsyy.com/News/0a6c1e58-e3d0-4cd1- 867a-d5524bc59cd6.html [accessed 22
March 2020].
17

Reuters (2020). China approves use of Roche drug in battle against coronavirus complications [online]. Website https://www.
reuters.com/article/us-health-coronavirus-china-roche-hldg/china-approves-use-of-roche-arthritis-drug-for-coronavirus-patientsidUSKBN20R0LF [accessed 10 April 2020].
18

Xu X, Han M, Li T, Sun W, Wang D et al. Effective treatment of severe COVID-19 patients with tocilizumab. ChinaXiv 2020;
202003.00026v1. doi: 10.1101/2020.04.08.029769
19

Duan K, Liu B, Li C, Zhang H, Yu T et al. The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study.
MedRxiv 2020. doi: 10.1101/2020.03.16.20036145
20
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limitations, findings suggest that the administration
of convalescent plasma is safe, reduces viral load, and
may improve clinical outcomes. Similarly, high-dose
intravenous immunoglobulin (IVIg) has been suggested
as a potential therapy for COVID-19 [60]; however,
supporting data are few and marred by potential
confounders.
8. Conclusion
As the whole world is going through hard times because
of the pandemic, health care workers are carrying out a
considerable effort to find new treatment modalities. There
is a very dynamic process on epidemiology and clinical
trials about the current pandemic globally. Many reports
are coming out every day. All these efforts are for saving
more lives. According to the data presented in this review,

this pandemic seems to have less risk for children than
adults. The main point for COVID-19 infection is ‘not to be
infected.’ Infection control precautions should be carried
out carefully. Herein, also, treatment recommendations
are summarized. In severe cases, antiviral drugs may also
be used, but it should be kept in mind that none of these
are proved for pediatric patients yet and not approved.
We wish ease and success to all healthcare workers,
governments, and humanity in fighting this pandemic.
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